AstraZeneca and the University of Oxford, the front runners in the delivery of the COVDI-19 vaccine, are facing mounting questions after acknowledging a manufacturing error in their trial results, according to Bloomberg. Astra and Oxford, which announced on Monday that their vaccine shot was 70% effective, did not disclose, in their original statement, that some participants in the trials received half a dose instead of a full one.
- Astra and Oxford did not disclose that their vaccine was administered half a dose to a younger population because of an error in the quantity of vaccine put into some trials, which raises credibility issues.
- Oxford has reiterated that when it was clear that a lower dose was issued, it was discussed with regulators, and an agreement reached to push ahead with the two regimens.
- Astra has said the trials were done to the highest standards, and more analysis is being done to refine the efficacy results.
AstraZeneca Inc.’s stock is trading slightly lower. AZN: LON is down 0067%
